Aberdeen Group’s Maze Therapeutics MAZE Stock Holding History

Aberdeen Group’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.75M	Buy	+226,227	New	+$9.98M	0.01%	654

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Aberdeen Group's MAZE Position: Q1 2026 in Review

Aberdeen Group opened a new position in Maze Therapeutics (MAZE) in Q1 2026: 226,227 shares worth $6.75M. The stake represents 0.01% of the portfolio and ranks #654 among its holdings.

165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

Aberdeen Group held 226,227 shares of Maze Therapeutics worth $6.75M as of Q1 2026.
Maze Therapeutics was a new Aberdeen Group position in Q1 2026.
Maze Therapeutics made up 0.01% of Aberdeen Group's portfolio in Q1 2026, its #654 holding.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.